Navigation Links
Safety Concerns Prompt Prime to Remove Avandia(R) from Formulary
Date:12/6/2007

ST. PAUL, Minn., Dec. 6 /PRNewswire/ -- Pharmacy benefit manager Prime Therapeutics (Prime) recently announced the removal of the prescription drug Avandia(R) from its national formulary. After careful examination of clinical literature regarding the safety and efficacy of Avandia, Prime's National Pharmacy and Therapeutics (P&T) Committee has made the decision to remove the drug from its formulary. Prime's P&T Committee is a panel of pharmacists and physicians that meets quarterly and reviews drugs for Prime's formulary.

In May 2007, a meta-analysis by Nissen, et al, suggested that Avandia significantly increased the risk of heart attack. The results of this meta-analysis were also duplicated by the Food and Drug Administration (FDA) and Avandia manufacturer, GlaxoSmithKline. Consequently, in November 2007, the FDA announced that a black boxed warning for an increased risk for heart attacks in some patients would be added to Avandia's prescribing information.

Following the May publication of the Avandia meta-analysis, Prime's outcome clinicians began an in-depth analysis of Avandia utilization. An analysis of medical and pharmacy claims revealed that over 25 percent of patients on Avandia had a history of coronary artery disease or heart failure. The clinical evidence indicated that the use of Avandia in these patients may increase cardiovascular risk. Since the meta-analysis was released in May, Prime has seen a 58 percent decline in Avandia utilization.

"Prime has made this decision after a thorough analysis of the clinical literature examining the safety and efficacy of Avandia. Prime's National P&T Committee is committed to ensuring the safety and quality of Prime's formulary medications," stated Craig Mattson, Prime's Senior Director of Drug Technology Assessment and Formulary Development. "Prime takes drug safety warnings very seriously and our primary concern is the safety of our members."

Prime is committed to communicating to physicians the safety concerns surrounding Avandia and all other medications. Prime will continue to follow all market events surrounding drug safety and will make formulary changes when necessary.

Prime Therapeutics LLC is a pharmacy benefit management company dedicated to providing innovative, clinically based, cost-effective pharmacy solutions for clients and members. Providing pharmacy benefit services nationwide to approximately 12.5 million covered lives, its client base includes Blue Cross and Blue Shield Plans, employer and union groups, and third-party administrators. Headquartered in St. Paul, Minnesota, Prime Therapeutics is collectively owned by 10 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those Plans. Learn more at http://www.primetherapeutics.com.


'/>"/>
SOURCE Prime Therapeutics LLC
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. More proof needed of safety and quality of electronic personal health records
2. Back to School Means Backpack Safety
3. Seniors Need a Safety Plan in Face of Disasters
4. New Survey Shows Americans are Still Concerned About Food Safety, Yet Still Not Smart About What They Like to Eat
5. National Patient Safety Foundation Partners with Vocera Communications
6. PA Governors Occupational Safety and Health Conference Still Accepting Registrations
7. QI projects may -- or may not -- improve patient safety and outcomes
8. The National Center for Missing & Exploited Children, Wal-Mart, and Abbott Host Child Safety Events
9. Cutting Salt Wont Affect Foods Safety
10. Microsoft Helps Developers of Clinical User Interfaces Improve Efficiency, Patient Safety With Free Toolkit
11. The Risk Management and Patient Safety Institute Announces Annual Health Care Risk Conference Dates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... , ... February 22, 2017 , ... ... regenerative medicine in recent years. The technology is so cutting edge, in fact, ... the protocol for stem cell procedures. However, successful patient outcomes in certain clinical ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... its certification exam and eligibility requirements effective with the April 2017 testing period. ... 1995. , “The Care Manager Certified (CMC) exam is periodically re-calibrated to ...
(Date:2/22/2017)... ... February 22, 2017 , ... VitreosHealth ... each Medicare Advantage member’s risk, identify any gaps-in-coding, as well as gaps-in-care ... transform the HCC Risk Adjustment process from a typical fragmented process to ...
(Date:2/22/2017)... ... February 22, 2017 , ... Doctors on Liens is continuing its steady expansion ... H. Rauchman, practicing at North Valley Eye Medical Group in Mission Hills . ... and other personal injury cases. These injuries have a major impact on the ...
(Date:2/22/2017)... ... February 22, 2017 , ... Using the power of the internet, ... online checklist. Over a period of just 24 months, thousands of individuals interested in ... checklist called T.A.D. , “The internet is not getting quieter. In fact it’s becoming ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company ... and market advanced products and therapies for the Wound ... sectors of healthcare, today announced its record results for ... 2016. Full Year 2016 Highlights are: ... full year 2015 revenue ...
(Date:2/23/2017)...   SeraCare Life Sciences , a manufacturer ... manufacturers and clinical laboratories, is announcing an upcoming ... Tests" to be hosted by GenomeWeb ... Standard Time (US). The goal of ... improved performance and global standardization in the implementation ...
(Date:2/23/2017)... , February 23, 2017 The U.S. ... legalized cannabis for recreational use in 2016. According to a ... market was worth an estimated $7.2 billion in 2016 and ... of 17%. While adult recreational sales are projected to jump ... with a 25% CAGR. The market may grow faster as ...
Breaking Medicine Technology: